Summarizing, in the light of published clinical data (summarized in the Table 1), anti-TNF-α treatment seems to reduce the risk of cardiovascular episodes mainly by inhibiting systemic inflammation and thereby suppressing the development of atherosclerosis and ischemic events. The gene discussed is TNF; the disease is atherosclerosis.